Getinge announced good Q3 20 numbers, as sales and adjusted EBITA rose strongly, thanks to Acute Care Therapies and Life Sciences, which offset the weakness in Surgical Workflows. The order intake (-5.3%) was the only sore spot in the quarter, suggesting the COVID-19-driven momentum was starting to fade. However, we will upgrade our FY20 estimates as we expect a strong Q4, and lower our FY 21 estimates due to phasing effects. Hence, we expect no significant target price impact.
19 Oct 2020
Q3 20 order decline is nothing to worry about
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 20 order decline is nothing to worry about
Getinge AB Class B (0GZV:LON), 0 | Getinge AB Class B (GETI.B:OME), 0 | Getinge AB Class B (GNGBF:OTC), 0 | Getinge AB Class B (GTN:FRA), 0
- Published:
19 Oct 2020 -
Author:
Virendra Chauhan -
Pages:
3
Getinge announced good Q3 20 numbers, as sales and adjusted EBITA rose strongly, thanks to Acute Care Therapies and Life Sciences, which offset the weakness in Surgical Workflows. The order intake (-5.3%) was the only sore spot in the quarter, suggesting the COVID-19-driven momentum was starting to fade. However, we will upgrade our FY20 estimates as we expect a strong Q4, and lower our FY 21 estimates due to phasing effects. Hence, we expect no significant target price impact.